Human stem cell-based retina on chip as new translational model for validation of AAV retinal gene therapy vectors.


Journal

Stem cell reports
ISSN: 2213-6711
Titre abrégé: Stem Cell Reports
Pays: United States
ID NLM: 101611300

Informations de publication

Date de publication:
14 09 2021
Historique:
received: 01 03 2021
revised: 16 08 2021
accepted: 16 08 2021
entrez: 15 9 2021
pubmed: 16 9 2021
medline: 11 3 2022
Statut: ppublish

Résumé

Gene therapies using adeno-associated viruses (AAVs) are among the most promising strategies to treat or even cure hereditary and acquired retinal diseases. However, the development of new efficient AAV vectors is slow and costly, largely because of the lack of suitable non-clinical models. By faithfully recreating structure and function of human tissues, human induced pluripotent stem cell (iPSC)-derived retinal organoids could become an essential part of the test cascade addressing translational aspects. Organ-on-chip (OoC) technology further provides the capability to recapitulate microphysiological tissue environments as well as a precise control over structural and temporal parameters. By employing our recently developed retina on chip that merges organoid and OoC technology, we analyzed the efficacy, kinetics, and cell tropism of seven first- and second-generation AAV vectors. The presented data demonstrate the potential of iPSC-based OoC models as the next generation of screening platforms for future gene therapeutic studies.

Identifiants

pubmed: 34525384
pii: S2213-6711(21)00426-4
doi: 10.1016/j.stemcr.2021.08.008
pmc: PMC8452599
pii:
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2242-2256

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Références

Bull World Health Organ. 2001;79(3):227-32
pubmed: 11285667
Stem Cells Dev. 2012 Apr 10;21(6):965-76
pubmed: 21699413
Expert Opin Drug Discov. 2019 Jan;14(1):47-57
pubmed: 30526132
Adv Genet. 2009;67:29-60
pubmed: 19914449
Drug Discov Today. 2019 Sep;24(9):1720-1724
pubmed: 31185290
Mol Ther. 2019 Jan 2;27(1):118-129
pubmed: 30528929
Elife. 2019 Aug 27;8:
pubmed: 31451149
Mol Ther. 2018 Mar 7;26(3):664-668
pubmed: 29428298
Mol Ther Methods Clin Dev. 2019 Jan 26;12:248-265
pubmed: 30815511
Front Genet. 2019 Sep 25;10:868
pubmed: 31608113
Sci Rep. 2016 Oct 19;6:35495
pubmed: 27759036
Nat Rev Drug Discov. 2021 May;20(5):345-361
pubmed: 32913334
Mol Ther. 2011 Apr;19(4):782-9
pubmed: 21285961
Prog Retin Eye Res. 2013 Jan;32:22-47
pubmed: 22995954
Mol Ther. 2002 Oct;6(4):490-4
pubmed: 12377190
Hum Gene Ther. 2018 Oct;29(10):1124-1139
pubmed: 29580100
EMBO Mol Med. 2021 Apr 9;13(4):e13392
pubmed: 33616280
Stem Cell Reports. 2021 Feb 9;16(2):252-263
pubmed: 33513359
Cell. 2020 Sep 17;182(6):1623-1640.e34
pubmed: 32946783
JCI Insight. 2020 May 21;5(10):
pubmed: 32271719
Int J Mol Sci. 2020 Jun 12;21(12):
pubmed: 32545533
Curr Opin Virol. 2017 Jun;24:124-131
pubmed: 28672171
PLoS One. 2009 Oct 14;4(10):e7467
pubmed: 19826483
Biotechnol Bioeng. 2016 Dec;113(12):2712-2724
pubmed: 27259396
PLoS One. 2012;7(7):e41958
pubmed: 22860038
Gene Ther. 2001 Aug;8(16):1248-54
pubmed: 11509958
Hum Gene Ther Methods. 2015 Aug;26(4):147-57
pubmed: 26222983
ACS Synth Biol. 2020 Jun 19;9(6):1292-1305
pubmed: 32427483
Cell Stem Cell. 2017 Sep 7;21(3):297-300
pubmed: 28886364
Sci Transl Med. 2013 Jun 12;5(189):189ra76
pubmed: 23761039
J Virol. 2007 Oct;81(20):11372-80
pubmed: 17699581
Front Neurosci. 2017 Apr 03;11:174
pubmed: 28420956
Int J Mol Sci. 2020 Feb 03;21(3):
pubmed: 32028585
ALTEX. 2020 Feb 28;37(3):365-394
pubmed: 32113184
Nat Commun. 2014 Jun 10;5:4047
pubmed: 24915161
Hum Gene Ther Methods. 2019 Feb;30(1):23-33
pubmed: 30693792
Trends Mol Med. 2018 Aug;24(8):669-681
pubmed: 29983335
Hum Gene Ther. 2018 Apr;29(4):424-436
pubmed: 29160116
Mol Ther Methods Clin Dev. 2018 Dec 01;13:55-66
pubmed: 30666309
Prog Retin Eye Res. 2020 Jul;77:100827
pubmed: 31899291

Auteurs

Kevin Achberger (K)

Institute of Neuroanatomy & Developmental Biology (INDB), Eberhard Karls University Tübingen, Tübingen, Germany.

Madalena Cipriano (M)

Department of Biomedical Engineering, Faculty of Medicine, Eberhard Karls University Tübingen, Tübingen, Germany.

Matthias J Düchs (MJ)

Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.

Christian Schön (C)

Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.

Stefan Michelfelder (S)

Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.

Birgit Stierstorfer (B)

Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.

Thorsten Lamla (T)

Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.

Stefan G Kauschke (SG)

Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.

Johanna Chuchuy (J)

Department of Biomedical Engineering, Faculty of Medicine, Eberhard Karls University Tübingen, Tübingen, Germany.

Julia Roosz (J)

NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.

Lena Mesch (L)

Institute of Neuroanatomy & Developmental Biology (INDB), Eberhard Karls University Tübingen, Tübingen, Germany.

Virginia Cora (V)

Institute of Neuroanatomy & Developmental Biology (INDB), Eberhard Karls University Tübingen, Tübingen, Germany.

Selin Pars (S)

Institute of Neuroanatomy & Developmental Biology (INDB), Eberhard Karls University Tübingen, Tübingen, Germany.

Natalia Pashkovskaia (N)

Institute of Neuroanatomy & Developmental Biology (INDB), Eberhard Karls University Tübingen, Tübingen, Germany.

Serena Corti (S)

Institute of Neuroanatomy & Developmental Biology (INDB), Eberhard Karls University Tübingen, Tübingen, Germany.

Sophia-Marie Hartmann (SM)

Institute of Neuroanatomy & Developmental Biology (INDB), Eberhard Karls University Tübingen, Tübingen, Germany.

Alexander Kleger (A)

Department of Internal Medicine I, University Hospital Ulm, Ulm, Germany.

Sebastian Kreuz (S)

Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.

Udo Maier (U)

Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.

Stefan Liebau (S)

Institute of Neuroanatomy & Developmental Biology (INDB), Eberhard Karls University Tübingen, Tübingen, Germany.

Peter Loskill (P)

Department of Biomedical Engineering, Faculty of Medicine, Eberhard Karls University Tübingen, Tübingen, Germany; NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany; 3R-Center for In vitro Models and Alternatives to Animal Testing, Eberhard Karls University Tübingen, Tübingen, Germany. Electronic address: peter.loskill@uni-tuebingen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH